Skip to main content
SpringerLink
Log in

Guillain-Barré Syndrome

Clinical Manifestations and Directions for Treatment

  • Practical Therapeutics
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Guillain-Barré syndrome (GBS) is the commonest cause of acute neuromuscular paralysis in the developed world today. Patients present most commonly with a rapidly ascending paralysis together with sensory symptoms and variable autonomic involvement. The diagnosis is clinical, but lumbar puncture and nerve conduction studies are helpful in excluding other conditions. The improvement in prognosis in recent years is largely due to advances in respiratory intensive care management. Careful monitoring of cardiorespiratory function and in particular regular measurements of the vital capacity will help to predict which patients will require elective ventilation to prevent impending neuromuscular respiratory failure.

The paralysed patient is susceptible to all the complications of immobility, in particular venous thromboembolism and hypostatic pneumonia, and good nursing care and physiotherapy are therefore mandatory. Autonomic involvement may predispose to cardiac arrhythmias and labile blood pressure. The prolonged nature of the illness predisposes to psychiatric complications, particularly depression, and this should be treated appropriately.

Specific treatment is aimed at reducing the period of maximum disability. Both plasma exchange (PE) and intravenous immune globulin (IVIg) have been shown to be effective in randomised controlled trials. A multicentre trial is currently under way to determine whether PE or IVIg or PE followed by IVIg is the most effective treatment for this condition. Steroids alone have not been shown to be of value, although a trial is under way comparing the combination of IVIg and methylprednisolone with IVIg alone.

The prognosis of GBS is generally good, with about 80% of patients making a full recovery, although about 5% die of complications. As yet, there is no specific additional treatment that can be given to patients in poor prognostic groups, and it is only with a better understanding of the immunopathological mechanisms underlying GBS that more effective and more specific therapies will become available.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hughes RAC, Rees JH. Guillain-Barré syndrome. Curr Opin Neurol 1994; 7: 386–92.

    Article  PubMed  CAS  Google Scholar 

  2. Arnason BGW, Soliven B. Acute inflammatory demyelinating polyradiculoneuropathy. In: Dyck PJ, Thomas PK, Griffin JW, et al., editors. Peripheral neuropathy. 3rd ed. Philadelphia: WB Saunders, 1993: 1437–97.

    Google Scholar 

  3. McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol 1993; 33: 333–42.

    Article  PubMed  CAS  Google Scholar 

  4. Sliman NA. Outbreak of Guillain-Barré syndrome associated with water pollution. BMJ 1978; 1: 751–2.

    Article  PubMed  CAS  Google Scholar 

  5. Rees JH, Gregson NA, Griffiths PL, et al. Campylobacter jejuni and Guillain-Barré syndrome. Q J Med 1993; 86: 623–34.

    PubMed  CAS  Google Scholar 

  6. Steele JG, Gladstone RM, Thanasophon S, et al. Mycoplasma pneumoniae as a determinant of the Guillain-Barré syndrome. Lancet 1969; 2: 710.

    Article  PubMed  CAS  Google Scholar 

  7. Dowling PC, Cook SB. Role of infection in Guillain-Barré syndrome: laboratory confirmation of herpes virus in 41 cases. Ann Neurol 1981; 9 Suppl.: 44–55.

    Article  PubMed  Google Scholar 

  8. Gautier-Smith PC. Neurological complications of glandular fever (infectious mononucleosis). Brain 1965; 88: 323.

    Article  PubMed  CAS  Google Scholar 

  9. Gross FJ, Mindel JS. Pseudotumor cerebri and Guillain-Barré syndrome associated with human immunodeficiency virus infection. Neurology 1991; 41: 1845–6.

    Article  PubMed  CAS  Google Scholar 

  10. Knittel TH, Ramadori G, Mayet WJ, et al. Guillain-Barré syndrome and human diploid cell rabies vaccine. Lancet 1989; 1: 1334–5.

    Article  PubMed  CAS  Google Scholar 

  11. Schonberger LB, Bregman DJ, Sullivan-Bolynai JZ, et al. Guillain-Barré syndrome following vaccination in the National Influenza Immunization program, United States 1976–1977. Am J Epidemiol 1979; 110: 105–23.

    PubMed  CAS  Google Scholar 

  12. Fagius J, Osterman PO, Siden A, et al. Guillain-Barré syndrome following zimelidine treatment. J Neurol Neurosurg Psychiat 1985; 48: 65–9.

    Article  PubMed  CAS  Google Scholar 

  13. Dick DJ, Raman D. The Guillain-Barré syndrome following gold therapy. Scand J Rheumatol 1982; 11: 119–23.

    Article  PubMed  CAS  Google Scholar 

  14. Knezevic W, Quintner J, Mataglia FL, et al. Guillain-Barré syndrome and pemphigus foliaceus associated with D-penicillamine therapy. Aust N Z J Med 1984; 14: 50–2.

    Article  PubMed  CAS  Google Scholar 

  15. Arrowsmith JB, Milstein JB, Kuritsky JN, et al. Streptokinase and the Guillain-Barré syndrome. Ann Intern Med 1985; 103: 302.

    PubMed  CAS  Google Scholar 

  16. Chakraborty TK, Ruddell WS. Guillain-Barré neuropathy during treatment with captopril. Postgrad Med J 1987; 63: 221–2.

    Article  PubMed  CAS  Google Scholar 

  17. Hory B, Blanc D, Boillot A, et al. Guillain-Barré syndrome following danazol and corticosteroid therapy for hereditary angioedema. Am J Med 1985; 79: 111–5.

    Article  PubMed  CAS  Google Scholar 

  18. Loizou LA, Boddie HG. Polyradiculoneuropathy associated with heroin abuse. J Neurol Neurosurg Psychiatry 1978; 41: 855–7.

    Article  PubMed  CAS  Google Scholar 

  19. Palace JA, Hughes RAC. Guillain-Barré syndrome with persistent severe disability: relationship to hyperacute Guillain-Barré syndrome. Eur J Neurol 1994; 1: 21–7.

    Article  Google Scholar 

  20. Miller Fisher. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 1956; 255: 57–65.

    Article  Google Scholar 

  21. Guillain G, Barré JA, Strohl A. Sur un syndrome de radiculonevrité avec hyperalbuminose du liquide céphalo-rachidien sans réaction cellulaire: remarques sur les caractères cliniques et graphiques des réflexes tendineux. Bull Soc Med Hop Paris 1916; 40: 1462–70.

    Google Scholar 

  22. Willison HJ, Veitch J, Paterson G, et al. Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside. J Neurol Neurosurg Psychiat 1993; 56: 204–6.

    Article  PubMed  CAS  Google Scholar 

  23. Gregson NA, Koblar S, Hughes RAC. Antibodies to gangliosides in Guillain-Barré syndrome: specificity and relationship to clinical features. Q J Med 1993; 86: 111–7.

    PubMed  CAS  Google Scholar 

  24. Ropper AH, Shahani BT. Pain in Guillain-Barré syndrome. Arch Neurol 1984; 41: 511–4.

    Article  PubMed  CAS  Google Scholar 

  25. Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985; 35: 1096–104.

    Article  Google Scholar 

  26. French Cooperative Group in Plasma Exchange in Guillain-Barré Syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 1987; 22: 753–61.

    Article  Google Scholar 

  27. Hughes RAC, Newsom-Davis JM, Perkin GD, et al. Controlled trial of predisolone in acute neuropathy. Lancet 1978; 2; 750–3.

    Article  PubMed  CAS  Google Scholar 

  28. Kleyweg RP, van der Meché FGA, Meulstee J. Treatment of Guillain-Barré syndrome with high-dose gammaglobulin. Neurology 1988; 38; 1639–41.

    Article  PubMed  CAS  Google Scholar 

  29. Van der Meché FGA, Schmitz PIM, Dutch Guillain-Barré Study Group. A randomised trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992; 326: 1123–9.

    Article  PubMed  Google Scholar 

  30. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994; 121: 259–62.

    PubMed  CAS  Google Scholar 

  31. Pasatiempo AMG, Kroser JA, Rudnick M, et al. Acute renal failure after intravenous immunoglobulin therapy. J Rheumatol 1994; 21: 347–9.

    PubMed  CAS  Google Scholar 

  32. Castro LHM, Ropper AH. Human immune globulin infusion in Guillain-Barré syndrome: worsening during and after treatment. Neurology 1993; 43: 1034–6.

    Article  PubMed  CAS  Google Scholar 

  33. Irani DN, Cornblath DR, Chaudhry V, et al. Relapse in Guillain-Barré syndrome after treatment with human immune globulin. Neurology 1993; 43: 872–5.

    Article  PubMed  CAS  Google Scholar 

  34. Epstein MA, Sladky JT. The role of plasmapheresis in childhood Guillain-Barré syndrome. Ann Neurol 1990; 28: 65–9.

    Article  PubMed  CAS  Google Scholar 

  35. Shahar E, Murphy EG, Roifman CM. Benefit of intravenously administered immune serum globulin in patients with Guillain-Barré syndrome. J Pediatr 1990; 116: 141–4.

    Article  PubMed  CAS  Google Scholar 

  36. Vajsar J, Sloane A, Wood E, et al. Plasmapheresis vs intravenous immunoglobulin treatment in childhood Guillain-Barré syndrome. Arch Pediatr Adolesc Med 1994; 148: 1210–2.

    Article  PubMed  CAS  Google Scholar 

  37. Guillain-Barré Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 1993; 341: 586–9.

    Google Scholar 

  38. Dutch Guillain-Barré Study Group. Treatment of Guillain-Barré syndrome with high dose immune globulins combined with methylprednisolone: a pilot study. Ann Neurol 1994; 35: 749–52.

    Article  Google Scholar 

  39. Archelos JJ, Mäurer M, Jung S, et al. Suppression of experimental allergic neuritis by an antibody to the intercellular adhesion molecule ICAM-1. Brain 1993; 116: 1043–58.

    Article  PubMed  Google Scholar 

  40. Winer JB, Hughes RAC, Osmond C. Aprospective study of acute idiopathic neuropathy: I. Clinical features and their prognostic value. J Neurol Neurosurg Psychiat 1988; 51: 605–12.

    Article  PubMed  CAS  Google Scholar 

  41. Yuki N, Taki T, Inagaki F, et al. A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J Exp Med 1993; 178: 1771–5.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, UMDS — Guy’s Hospital, Royal Free Hospital, London, NW3, England

    Jeremy Rees

Authors
  1. Jeremy Rees
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rees, J. Guillain-Barré Syndrome. Drugs 49, 912–920 (1995). https://doi.org/10.2165/00003495-199549060-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199549060-00005

Keywords

Search

Navigation